Many pharmaceutical companies operating in Japan are facing a period of unprecedented pressure. Mounting challenges include price cuts, ongoing patent expirations, the increasing uptake of generics, and the seemingly immutable costs of a large, non-specialty sales force. Many pharma companies — small and large, local and multinational — will face considerable financial strain in the coming years as some struggle to reposition themselves for profitable growth or even long-term viability. However, those that can identify and focus on their true strengths, build value-oriented portfolios, and upgrade the analytics driving their operations will be best able to differentiate and win.

In this Special Report, L.E.K. Consulting proposes a range of tactics and strategies to help pharmaceutical companies in Japan navigate near-term profitability pressures; position themselves for efficient, profitable growth over the longer term; and potentially forge a path to market leadership.